Sergio M. Siragusa

Palermo, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 148 publications

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience.

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience.

Journal: Haematologica
Published: March 12, 2026

Estimated Whole Blood Viscosity in Smoldering Multiple Myeloma: Preliminary Data from a Retrospective Single Center Analysis.

Estimated Whole Blood Viscosity in Smoldering Multiple Myeloma: Preliminary Data from a Retrospective Single Center Analysis.

Journal: Journal of blood medicine
Published: March 03, 2026

Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions.

Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions.

Journal: International journal of molecular sciences
Published: February 27, 2026

Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.

Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.

Journal: Annals of hematology
Published: January 30, 2026

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Journal: Hematological oncology
Published: November 13, 2025

Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma.

Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma.

Journal: Frontiers in medicine
Published: November 04, 2025

Nutritional factors and survival in a cohort of patients with myelofibrosis.

Nutritional factors and survival in a cohort of patients with myelofibrosis.

Journal: Frontiers in nutrition
Published: September 14, 2025

Monoclonal Gammopathy Prevalence in Newly Diagnosed Prostate Cancer Patients: A Correlative Perspective Observational Study.

Monoclonal Gammopathy Prevalence in Newly Diagnosed Prostate Cancer Patients: A Correlative Perspective Observational Study.

Journal: Cancers
Published: September 01, 2025

Inflammatory Biomarkers for Thrombotic Risk Assessment in Multiple Myeloma Patients on IMiD/aCD38-Based Regimens: Insights from a Prospective Observational Study.

Inflammatory Biomarkers for Thrombotic Risk Assessment in Multiple Myeloma Patients on IMiD/aCD38-Based Regimens: Insights from a Prospective Observational Study.

Journal: Biomolecules
Published: August 31, 2025

Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response.

Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response.

Journal: Blood neoplasia
Published: April 01, 2025

Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.

Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.

Journal: Annals of hematology
Published: March 25, 2025

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study.

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study.

Journal: Hematological oncology
Published: March 24, 2025
Showing 1-12 of 148

Last Updated: 09/26/2026